Abstract:Radiotherapy for ultracentral lung tumors represents a treatment challenge, considering the high rates of high-grade treatment-related toxicities with stereotactic body radiation therapy (SBRT) or hypofractionated schedules. Accelerated hypofractionated magnetic resonance-guided adaptive radiation therapy (MRgART) emerged as a potential game-changer for tumors in these challenging locations, in close proximity to central organs at risk, such as the trachea, proximal bronchial tree, and esophagus. In this series, 13 consecutive patients, predominantly male (n = 9), with a median age of 71 (range (R): 46–85), underwent 195 MRgART fractions (all 60 Gy in 15 fractions) to metastatic (n = 12) or primary ultra-central lung tumors (n = 1). The median gross tumor volumes (GTVs) and planning target volumes (PTVs) were 20.72 cc (R: 0.54–121.65 cc) and 61.53 cc (R: 3.87–211.81 cc), respectively. The median beam-on time per fraction was 14 min. Adapted treatment plans were generated for all fractions, and indications included GTV/PTV undercoverage, OARs exceeding tolerance doses, or both indications in 46%, 18%, and 36% of fractions, respectively. Eight patients received concurrent systemic therapies, including immunotherapy (four), chemotherapy (two), and targeted therapy (two). The crude in-field loco-regional control rate was 92.3%. No CTCAE grade 3+ toxicities were observed. Our results offer promising insights, suggesting that MRgART has the potential to mitigate toxicities, enhance treatment precision, and improve overall patient care in the context of ultracentral lung tumors.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: for tumors located in the central area of the lung (ultra - central lung tumors), how to accelerate hypofractionated magnetic resonance - guided adaptive radiotherapy (MRgART) to reduce treatment - related toxicity, improve treatment accuracy, and enhance the overall care of patients. ### Background and Problems 1. **Treatment Challenges**: - For ultra - central lung tumors, when using traditional stereotactic body radiotherapy (SBRT) or hypofractionated regimens, high - dose treatment will lead to a relatively high level of high - grade treatment - related toxicity. - These tumors are usually close to central organs (such as the trachea, main bronchial tree, and esophagus), making the treatment more complicated. 2. **Limitations of Existing Methods**: - SBRT is suitable for small - volume tumors far from critical organs, but for large - volume central tumors, traditional fractionation regimens are still commonly used. - More aggressive hypofractionated regimens can improve the local control rate, but will increase the risk of treatment - related adverse events, especially damage to the trachea, main bronchial tree, and esophagus. ### Solutions 1. **Accelerated Hypofractionated Magnetic Resonance - guided Adaptive Radiotherapy (MRgART)**: - **Technical Advantages**: - Magnetic resonance imaging (MRI) provides superior soft - tissue visualization and can display mediastinal anatomical structures in detail. - Real - time continuous cine - MRI imaging is helpful for gated radiotherapy and reduces the overlap between high - dose areas and critical central organs. - Daily dosimetric evaluation is carried out to compare the original treatment plan with the anatomical changes before treatment on the same day and evaluate the dosimetric differences. - If necessary, a new adaptive plan can be generated on the treatment table to cope with new anatomical changes. 2. **Research Objectives**: - To evaluate the treatment effects of MRgART in ultra - central lung tumors, including treatment characteristics, dosimetric evaluation, and early clinical results. - To explore whether MRgART can effectively reduce treatment - related toxicity, improve treatment accuracy, and enhance the overall care of patients. ### Conclusions - **Preliminary Results**: - Thirteen patients received MRgART treatment with a total dose of 60 Gy in 15 fractions. - No CTCAE grade 3 or higher toxicity occurred. - The local control rate was 92.3%. - Multiple online plan adjustments were made during the treatment process to ensure target coverage and dose limitations of critical organs. - **Potential Impact**: - MRgART provides a new solution for the treatment of ultra - central lung tumors and is expected to improve the treatment effect and the quality of life of patients while reducing treatment - related toxicity. Through these studies, the authors hope to provide clinicians with a safer and more effective treatment option, especially when dealing with tumors located in the central area of the lung.

Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors

Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions

Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations

Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows

Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics Considerations

Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation

Use of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Oligometastatic Lung Adenocarcinoma: Leveraging CT-Guided Online Adaptive Radiotherapy

Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors

MR-guided online adaptive stereotactic body radiotherapy (MRgSBRT) of primary lung tumors and lung oligometastases

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

The First Reported Case of Treating the Ultra-Central Thorax With Cone Beam Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR)

Using adaptive magnetic resonance image‐guided radiation therapy for treatment of inoperable pancreatic cancer

Recent Advances and Current Challenges in Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors

Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy

CT-Guided Online Adaptive Radiotherapy Delivered via Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) for a Bulky Thoracic and Abdominal Mass in Oligometastatic Renal Cell Carcinoma

Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review

Efficacy of Online Adaptive Radiotherapy Using Surface Guidance in Treatment of Tracheal Adenoid Cystic Carcinoma

High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes

Feasibility of Adaptive Radiation Therapy for Human-Papilloma Virus-Positive Oropharyngeal Cancer Patients Using MR-Guided RT